title: Spectrum of disease outcomes in mice infected with YFV-17D.
abstract: The host and viral factors that influence disease outcome during flavivirus infections are not fully understood. Using the live attenuated yellow fever virus (YFV) vaccine strain 17D as a model system we evaluated how viral dose, inoculation route and immunopathogenesis contributed to disease outcome in mice deficient in the type I IFN response. We found that YFV-17D infection of IFN-α/β receptor knockout mice resulted in three distinct disease outcomes: no clinical signs of disease, fatal viscerotropic disease or fatal neurotropic disease. Interestingly, viral load at disease onset did not correlate with disease outcome. However, we found increased immune infiltrates in the brain tissues of mice that developed neurotropic disease. Additionally, mice that developed viscerotropic disease, as characterized by liver and spleen pathology and/or intestinal haemorrhage, had significantly elevated levels of alanine aminotransferase, monocyte chemotactic protein and IFN-inducible protein (IP)-10 as compared with mice with no clinical signs of disease or neurotropic disease. Furthermore, mice treated with recombinant IP-10 throughout YFV-17D infection showed increased mortality and an increased percentage of mice with viscerotropic disease. Our results demonstrated that viral load did not correlate with pathogenesis, and the host immune response played a pivotal role in disease outcome and contributed to YFV-17D pathogenesis in mice.
authors: Department of Microbiology, University of Texas Southwestern Medical Center, 5323 Harry Hines Blvd, Dallas, TX 75390-9048, USA.
authors: Andrea K
authors: AK
authors: Erickson
authors: Department of Microbiology, University of Texas Southwestern Medical Center, 5323 Harry Hines Blvd, Dallas, TX 75390-9048, USA.
authors: Julie K
authors: JK
authors: Pfeiffer
mesh_terms: D000410:Alanine Transaminase / Q000097:blood; D000818:Animals; D001921:Brain / Q000473:pathology; D018932:Chemokine CCL2 / Q000097:blood; D054357:Chemokine CXCL10 / Q000097:blood; D004195:Disease Models, Animal; D006471:Gastrointestinal Hemorrhage; D007370:Interferon Type I / Q000172:deficiency; D007422:Intestines / Q000473:pathology; D008099:Liver / Q000473:pathology; D008810:Mice, Inbred C57BL; D018345:Mice, Knockout; D013154:Spleen / Q000473:pathology; D016019:Survival Analysis; D019562:Viral Load; D015004:Yellow Fever / Q000473:pathology* / Q000821:virology*; D015005:Yellow fever virus / Q000502:physiology*
chemical_list: D018932:Chemokine CCL2; D054357:Chemokine CXCL10; C485433:Cxcl10 protein, mouse; D007370:Interferon Type I; D000410:Alanine Transaminase
references: J Virol. 2008 Jun;82(12):6024-33
references: 18400851
references: Annu Rev Pathol. 2013 Jan 24;8:411-40
references: 23121052
references: J Med Assoc Thai. 2002 Jan;85(1):131-4
references: 12075714
references: J Gen Virol. 2006 Oct;87(Pt 10):2791-801
references: 16963737
references: JAMA. 1966 Nov 7;198(6):671-2
references: 4380787
references: PLoS One. 2012;7(12):e52215
references: 23284941
references: MMWR Morb Mortal Wkly Rep. 2002 Nov 8;51(44):989-93
references: 12455906
references: Lancet. 2001 Jul 14;358(9276):91-7
references: 11463409
references: Antiviral Res. 2008 Apr;78(1):116-24
references: 18061688
references: Hum Vaccin. 2006 Mar-Apr;2(2):60-7
references: 17012873
references: PLoS One. 2012;7(9):e46292
references: 23050007
references: Proc Natl Acad Sci U S A. 1962 Feb;48:160-5
references: 13900302
references: Virology. 2007 Nov 25;368(2):422-30
references: 17675128
references: PLoS Negl Trop Dis. 2007 Nov 21;1(2):e86
references: 18060089
references: J Virol. 2005 Apr;79(7):4460-9
references: 15767446
references: PLoS Pathog. 2009 Oct;5(10):e1000614
references: 19816561
references: Science. 1986 Aug 15;233(4765):770-4
references: 3016895
references: Proc Natl Acad Sci U S A. 1931 Jun;17(6):339-43
references: 16587631
references: Nat Med. 2004 Dec;10(12):1366-73
references: 15558055
references: Proc Natl Acad Sci U S A. 2007 Oct 23;104(43):17140-5
references: 17939996
references: J Immunol. 2013 Oct 15;191(8):4194-201
references: 24043884
references: Curr Opin Infect Dis. 2005 Oct;18(5):387-94
references: 16148524
references: Proc Natl Acad Sci U S A. 1987 Apr;84(7):2019-23
references: 3470774
references: J Virol. 2013 Apr;87(7):3655-67
references: 23302887
references: Cytokine Growth Factor Rev. 2011 Jun;22(3):121-30
references: 21802343
references: Int J Exp Pathol. 1990 Dec;71(6):857-69
references: 2177623
references: Nat Immunol. 2009 Jan;10(1):116-125
references: 19029902
references: J Int Med Res. 2012;40(2):648-56
references: 22613426
references: J Virol. 2013 Nov;87(22):12392-7
references: 24027319
references: Lancet. 2001 Jul 14;358(9276):121-2
references: 11463415
references: MMWR Recomm Rep. 2002 Nov 8;51(RR-17):1-11; quiz CE1-4
references: 12437192
references: J Virol. 2001 Mar;75(5):2107-18
references: 11160715
references: J Gen Virol. 1980 Jan;46(1):1-13
references: 6766176
references: Science. 1930 Apr 4;71(1840):367
references: 17731835
references: South Med J. 2005 Jun;98(6):653-6
references: 16004173
references: Am J Trop Med Hyg. 1963 Sep;12:815-9
references: 14070776
references: J Immunol. 2006 Aug 1;177(3):1855-63
references: 16849497
references: J Gen Virol. 1986 Apr;67 ( Pt 4):631-7
references: 3958694
references: J Exp Med. 1943 Jun 1;77(6):487-506
references: 19871299
references: Clin Vaccine Immunol. 2010 Jan;17(1):118-26
references: 19906894
references: J Med Virol. 1981;8(2):103-17
references: 7299376
references: J Infect Dis. 2014 Feb 1;209(3):334-44
references: 24141982
references: Neuron. 1991 Jun;6(6):957-69
references: 1711350
references: J Med Virol. 2004 Nov;74(3):507-13
references: 15368509
references: Arch Virol. 1983;76(1):51-61
references: 6860148
references: Virology. 2005 Nov 25;342(2):167-76
references: 16150475
references: Proc Natl Acad Sci U S A. 2006 Apr 25;103(17):6694-9
references: 16617103
references: PLoS Negl Trop Dis. 2010 Oct 05;4(10):
references: 20957152
references: Am J Trop Med Hyg. 2007 Nov;77(5):919-24
references: 17984354
references: J Infect Dis. 2008 Jun 1;197(11):1577-84
references: 18419548
references: J Immunol. 1971 Jul;107(1):236-43
references: 4326399
references: Virology. 1998 Oct 10;250(1):67-75
references: 9770421
references: J Infect Dis. 2003 Oct 15;188(8):1213-30
references: 14551893
references: Vaccine. 2010 Jan 8;28(3):632-49
references: 19808029
references: J Virol. 2005 Sep;79(17):11457-66
references: 16103196
references: Vaccine. 2007 Dec 5;25(50):8480-5
references: 18023511
references: Vaccine. 2012 May 2;30(21):3180-7
references: 22425792
references: Adv Virus Res. 2003;60:343-95
references: 14689698
references: J Virol. 2008 Sep;82(17):8411-21
references: 18562532
references: Lancet. 2001 Jul 14;358(9276):98-104
references: 11463410
references: J Infect Dis. 2004 Nov 15;190(10):1821-7
references: 15499539
references: J Gen Virol. 2006 Dec;87(Pt 12):3623-30
references: 17098977